16889-72-8

Upstream product

• 79-30-1 isobutyryl chloride 
• 75-65-0 tert-butyl alcohol 
• 4122-53-6 1-(1H-imidazol-1-yl)-2-methylpropan-1-one 
• 79-31-2 isobutyric Acid 
• 115-11-7 isobutene 
• 97-62-1 Ethyl isobutyrate 
• 97-72-3 2-Methylpropionic anhydride 
• 75665-42-8 4-Benzyliden-1-isobutyryl-1,4-dihydropyridin 
• 540-88-5 acetic acid tert-butyl ester 
• 547-63-7 Methyl isobutyrate 
• 75-91-2 tert.-butylhydroperoxide 
• 556-91-2 aluminum tri-tert-butoxide 
• 585-07-9 tert-Butyl methacrylate 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 53935-56-1 tert-butyl 2,2-dimethyl-3-oxo-3-phenylpropanoate 
• 2901-24-8 tert-butyl 2-methyl-2-phenylpropionate 
• 100-66-3 methoxybenzene 
• 82185-54-4 t-Butyl 2-phenylaminosulfinyl-2-methylpropanoate 
• 88830-21-1 5-isopropylbenzene-1,2,4-tricarbonitrile 
• 808760-26-1 t-butyl 2,2-dimethyl-3-diphenylphosphatoxyheptanoate 
• 929634-12-8 t-butyl 3-hydroxy-2,2-dimethyl-8,8-diphenyl-7-heptenoate 
• 409097-20-7 3-(4-bromo-phenyl)-2,2-dimethyl-propionic acid tert-butyl ester 
• 791627-01-5 (C₅H₅)2Zr(OC₄⁽²⁾H₈)(O₂CCH(CH₃)2)⁽¹⁺⁾*CH₃B(C₆F₅)3^(1-)=((C₅H₅)2Zr(OC₄⁽²⁾H₈)(O₂CCH(CH₃)2))(CH₃B(C₆F₅)3) 
• 1258239-53-0 3-(2-chloro-phenyl)-2-methyl-propionic acid tert-butyl ester 
• 1258239-33-6 C₁₄H₁₉FO₂ 
• 1258239-32-5 3-(2-fluoro-phenyl)-2-methylpropionic acid tert-butyl ester 
• 1258239-50-7 3-(2-fluoro-phenyl)-2-methylpropionic acid tert-butyl ester 
• 1258239-30-3 2-(3-fluoro-phenyl)-2-methyl-propionic acid tert-butyl ester 

Relevant academic research and scientific papers

STAPLED PEPTIDES AND METHODS THEREOF

Among other things, the present disclosure provides various agents. In some embodiments, provided agents can bind to beta-catenin. In some embodiments, the present disclosure provides technologies for modulating beta-catenin functions. In some embodiments, the present disclosure provides technologies for preventing and/or treating conditions, disorders or diseases associated with beta-catenin. In some embodiments, the present disclosure provides designed amino acids which can provide improved properties and/or activities. In some embodiments, the present disclosure provides agents comprising such amino acids.

AMINO ACIDS

In some embodiments, the present disclosure provides amino acid compounds that are useful for producing products such as peptides. In some embodiments, the present disclosure provides peptides comprising residues of provided amino acids.

HETEROARYLDIHYDROPYRIMIDINE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION

Sultam compounds, pharmaceutical compositions containing them, methods of making them, and methods of using them including methods for treating disease states, disorders, and conditions associated with the KEAP1-Nrf2 interaction, such as inflammatory bowel disease, including Crohn's disease and ulcerative colitis.

Alternatives for Conventional Alkane Solvents

The studies described in this paper show that hydrocarbon oligomers are alternatives for low molecular weight alkane solvents. These oligomeric solvents are nontoxic, nonvolatile, and recyclable alternatives to heptane in thermomorphic solvent mixtures th

HETEROBICYCLIC COMPOUNDS

Heterobicyclic compounds of Formula (I): or a pharmaceutically-acceptable salt, tautomer, or stereoisomer thereof, as defined in the specification, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, Huntington's Disease, and the like.

H-transfer reaction during decomposition of N-(2-methylpropyl)- N-(1-diethylphosphono-2,2-dimethylpropyl)-N-oxyl (SG1)-based alkoxyamines

Thermal decomposition of four tertiary N-(2-methylpropyl)-N-(1- diethylphosphono-2,2-dimethylpropyl)-N-oxyl (SG1)-based alkoxyamines (SG1-C(Me)2-C(O)-OR, R = Me, tBu, Et, H) has been studied at different experimental conditions using 1/su

Palladium-catalyzed β arylation of carboxylic esters

Alter ego: In the presence of an appropriate palladium(0) catalyst, carboxylic esters underwent β arylation instead of the more common α-arylation reaction with aryl halides containing an ortho electronegative substituent (see scheme; Cy = cyclohexyl). An asymmetric version of the reaction gave the product with an enantiomeric ratio of up to 77:23.

Domino catalysis in the direct conversion of carboxylic acids to esters

The combined use of high concentration conditions, auxiliary bases, and new catalysts allows for the rapid synthesis of sterically hindered carboxylic acid esters at room temperature. Mechanistic analysis indicates the intermediate formation of acid anhydrides and subsequent rate-limiting transformation to the ester products.

Propionic acid derivatives

The present application relates to novel potent PPAR-alpha-activating compounds for treating, for example, coronary heart disease, and to their preparation.